Abcam, ab112259, Recombinant Human RUNX2 protein

Size: 10µg
Recombinant Human RUNX2 protein is a Human Fragment protein, in the 311 to 450 aa range, expressed in Wheat germ, suitable for SDS-PAGE, ELISA, WB.
Key facts
Expression system:Wheat germ,
Tags:GST tag N-Terminus,
Applications:WB, SDS-PAGE, ELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:Q13950,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 8Constituents: 0.79% Tris HCl, 0.31% Glutathione

Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RUNX2 also known as core-binding factor subunit alpha-1 (CBFA1) is a transcription factor with a molecular weight of approximately 56 kDa. It plays a pivotal role in regulating osteoblast differentiation and skeletal morphogenesis. This protein resides mainly in the nucleus and shows a high expression in bone tissue. RUNX2 binds to DNA sequences to control transcription of genes essential for bone development and maturation. The protein also possesses a Runt-homology domain enabling it to attach to specific DNA sequences.
Biological function summary
This protein orchestrates bone formation by influencing the expression of genes involved in osteoblast differentiation. RUNX2 operates as part of the larger transcriptional complex that includes other proteins that modulate its activity. It maintains bone homeostasis by regulating the expression of osteogenic markers including bone sialoprotein and osteocalcin. The ability of RUNX2 to drive osteoblast lineage commitment highlights its importance in skeletal health and development.
Pathways
RUNX2 shows significant involvement in both the Wnt signaling and TGF-beta signaling pathways. Within the Wnt signaling pathway RUNX2 interacts with beta-catenin to facilitate osteoblastogenesis and support bone matrix deposition. In the TGF-beta signaling pathway RUNX2 modulates Smad-dependent transcriptional activity important for extracellular matrix production and bone remodeling. These interactions illustrate RUNX2's central role in mediating bone development and maintenance.
RUNX2 mutations and dysregulation link to cleidocranial dysplasia a condition characterized by delayed closure of sutures in the skull and other skeletal anomalies. Additionally RUNX2 is related to osteosarcoma a type of bone cancer where its abnormal expression often contributes to tumor progression. In these contexts RUNX2 interacts with proteins like p53 an important regulator of cell cycle highlighting its influence on tumor suppressor networks and osteogenic pathways.